Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740375 | 0.98 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL858370 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL30424732 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL29419589 | 0.78 | CA2 (0.56) | MAPTALDH1A1POLBTSHRKDM4E | |
| SCHEMBL20509 | 0.78 | CA2 (0.56) | MAPTALDH1A1POLBTSHRKDM4E | |
| SCHEMBL15969085 | 0.78 | HPGD (0.42) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL30214873 | 0.78 | HPGD (0.42) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL1129397 | 0.78 | MAPT (0.48) | MAPTALDH1A1GAAPOLBRECQL | |
| SCHEMBL2878953 | 0.77 | CSNK2A1 (0.43) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL2848535 | 0.77 | TSHR (0.47) | MAPTALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116554009-A | Electrophilic cross-coupling reaction method of aryl sulfone or heteroaryl sulfone and aryl bromide | 南京工业大学 | 2023-08-08 | — | — | CN | claimed |
| CN-114685251-B | Direct cross-coupling reaction method of diaryl sulfoxide and aryl bromide | 南京工业大学 | 2022-12-27 | — | — | CN | claimed |
| CN-114685251-A | Direct cross-coupling reaction method of diaryl sulfoxide and aryl bromide | 南京工业大学 | 2022-07-01 | — | — | CN | claimed |
| CN-109180578-A | A kind of preparation method of bosutinib | 山东创新药物研发有限公司 | 2019-01-11 | — | — | CN | claimed |
| US-5502186-A | Process for preparing intermediates for the synthesis of D1 antagonists | SCHERING CORPORATION (US) | 1996-03-26 | — | — | US | claimed |
| WO-1995009155-A2 | PROCESS AND INTERMEDIATES FOR THE ENANTIOSPECIFIC SYNTHESIS OF BENZO [D]NAPHTH[2,1-B]AZEPINES | SCHERING CORPORATION (US) | 1995-04-06 | — | — | WO | claimed |
| JP-9003082-A | — | — | None | — | — | JP | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4674852-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | Innovstone Therapeutics Limited (CN) | 2026-01-07 | — | — | EP | disclosed |
| EP-4630403-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2025-10-15 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| WO-1989000561-A1 | FUSED BENZAZEPINES | SCHERING CORPORATION (US) | 1989-01-26 | — | — | WO | disclosed |
| EP-0299101-A1 | Fused benzazepines | SCHERING CORPORATION (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0175452-B1 | 1,3-DISUBSTITUTED PIPERIDINE COMPOUNDS AS NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1988-09-21 | — | — | EP | disclosed |
| US-4623728-A | NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| US-4593037-A | Compound substituted with phenyl rings | PFIZER INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0175452-A1 | 1,3-Disubstituted piperidine compounds as neuroleptic agents | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4238611-A | Polysubstituted derivatives of 10-piperazinodibenzo (b,f) thiepine | SPOFA, UNITED PHARMACEUTICAL WORKS (CS) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | MAPT 4555/4885ALDH1A1 2085/4885MEN1 4497/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | MAPT 4528/4885ALDH1A1 4331/4885MEN1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.